vs
简柏特（EGP）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是简柏特的1.0倍（$197.9M vs $190.3M），简柏特净利率更高（49.7% vs 6.7%，领先43.0%），REPLIGEN CORP同比增速更快（13.6% vs 9.1%），简柏特自由现金流更多（$126.7M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 9.4%）
简柏特是全球领先的信息技术服务、咨询及外包服务商，总部位于美国纽约，注册地为百慕大，最初创立于印度古尔冈。目前公司全球员工超12.5万名，服务覆盖30余个国家，于纽交所上市，2023年营收达44.8亿美元。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
EGP vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.0倍
$190.3M
营收增速更快
RGEN
高出4.6%
9.1%
净利率更高
EGP
高出43.0%
6.7%
自由现金流更多
EGP
多$109.2M
$17.6M
两年增速更快
RGEN
近两年复合增速
9.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $190.3M | $197.9M |
| 净利润 | $94.6M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | — | 9.0% |
| 净利率 | 49.7% | 6.7% |
| 营收同比 | 9.1% | 13.6% |
| 净利润同比 | 59.2% | 143.9% |
| 每股收益（稀释后） | $1.77 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EGPRGEN
| Q1 26 | $190.3M | — | ||
| Q4 25 | $187.5M | $197.9M | ||
| Q3 25 | $182.1M | $188.8M | ||
| Q2 25 | $177.3M | $182.4M | ||
| Q1 25 | $174.4M | $169.2M | ||
| Q4 24 | $164.0M | $174.1M | ||
| Q3 24 | $162.9M | $154.9M | ||
| Q2 24 | $159.1M | $154.1M |
净利润EGPRGEN
| Q1 26 | $94.6M | — | ||
| Q4 25 | $67.8M | $13.3M | ||
| Q3 25 | $67.0M | $14.9M | ||
| Q2 25 | $63.3M | $14.9M | ||
| Q1 25 | $59.4M | $5.8M | ||
| Q4 24 | $58.7M | $-30.3M | ||
| Q3 24 | $55.2M | $-654.0K | ||
| Q2 24 | $55.3M | $3.3M |
毛利率EGPRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% |
营业利润率EGPRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 9.0% | ||
| Q3 25 | — | 8.9% | ||
| Q2 25 | — | 7.6% | ||
| Q1 25 | — | 3.9% | ||
| Q4 24 | — | -17.7% | ||
| Q3 24 | — | -5.1% | ||
| Q2 24 | — | 1.0% |
净利率EGPRGEN
| Q1 26 | 49.7% | — | ||
| Q4 25 | 36.1% | 6.7% | ||
| Q3 25 | 36.8% | 7.9% | ||
| Q2 25 | 35.7% | 8.2% | ||
| Q1 25 | 34.1% | 3.4% | ||
| Q4 24 | 35.8% | -17.4% | ||
| Q3 24 | 33.9% | -0.4% | ||
| Q2 24 | 34.8% | 2.2% |
每股收益（稀释后）EGPRGEN
| Q1 26 | $1.77 | — | ||
| Q4 25 | $1.27 | $0.24 | ||
| Q3 25 | $1.26 | $0.26 | ||
| Q2 25 | $1.20 | $0.26 | ||
| Q1 25 | $1.14 | $0.10 | ||
| Q4 24 | $1.17 | $-0.55 | ||
| Q3 24 | $1.13 | $-0.01 | ||
| Q2 24 | $1.14 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.4M | $767.6M |
| 总债务越低越好 | $1.6B | $542.2M |
| 股东权益账面价值 | $3.6B | $2.1B |
| 总资产 | $5.5B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.45× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资EGPRGEN
| Q1 26 | $31.4M | — | ||
| Q4 25 | $1.0M | $767.6M | ||
| Q3 25 | $3.0M | $748.7M | ||
| Q2 25 | $32.9M | $708.9M | ||
| Q1 25 | $20.5M | $697.2M | ||
| Q4 24 | $17.5M | $757.4M | ||
| Q3 24 | $17.0M | $784.0M | ||
| Q2 24 | $39.4M | $809.1M |
总债务EGPRGEN
| Q1 26 | $1.6B | — | ||
| Q4 25 | — | $542.2M | ||
| Q3 25 | $1.4B | $537.9M | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | $525.6M | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.7B | — |
股东权益EGPRGEN
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.5B | $2.1B | ||
| Q3 25 | $3.5B | $2.1B | ||
| Q2 25 | $3.4B | $2.1B | ||
| Q1 25 | $3.3B | $2.0B | ||
| Q4 24 | $3.3B | $2.0B | ||
| Q3 24 | $2.8B | $2.0B | ||
| Q2 24 | $2.8B | $2.0B |
总资产EGPRGEN
| Q1 26 | $5.5B | — | ||
| Q4 25 | $5.4B | $2.9B | ||
| Q3 25 | $5.4B | $2.9B | ||
| Q2 25 | $5.2B | $2.9B | ||
| Q1 25 | $5.1B | $2.9B | ||
| Q4 24 | $5.1B | $2.8B | ||
| Q3 24 | $4.8B | $2.8B | ||
| Q2 24 | $4.7B | $2.9B |
负债/权益比EGPRGEN
| Q1 26 | 0.45× | — | ||
| Q4 25 | — | 0.26× | ||
| Q3 25 | 0.41× | 0.26× | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.43× | — | ||
| Q4 24 | 0.46× | 0.27× | ||
| Q3 24 | 0.57× | — | ||
| Q2 24 | 0.60× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $142.3M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $126.7M | $17.6M |
| 自由现金流率自由现金流/营收 | 66.6% | 8.9% |
| 资本支出强度资本支出/营收 | 8.2% | 4.1% |
| 现金转化率经营现金流/净利润 | 1.50× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $771.1M | $93.9M |
8季度趋势，按日历期对齐
经营现金流EGPRGEN
| Q1 26 | $142.3M | — | ||
| Q4 25 | $480.7M | $25.7M | ||
| Q3 25 | $138.9M | $48.1M | ||
| Q2 25 | $143.4M | $28.6M | ||
| Q1 25 | $133.7M | $15.0M | ||
| Q4 24 | $416.6M | $39.2M | ||
| Q3 24 | $122.9M | $49.3M | ||
| Q2 24 | $122.9M | $42.2M |
自由现金流EGPRGEN
| Q1 26 | $126.7M | — | ||
| Q4 25 | $404.9M | $17.6M | ||
| Q3 25 | $120.3M | $43.4M | ||
| Q2 25 | $119.2M | $21.5M | ||
| Q1 25 | $113.9M | $11.4M | ||
| Q4 24 | $357.3M | $33.6M | ||
| Q3 24 | $108.5M | $42.3M | ||
| Q2 24 | $102.8M | $37.4M |
自由现金流率EGPRGEN
| Q1 26 | 66.6% | — | ||
| Q4 25 | 216.0% | 8.9% | ||
| Q3 25 | 66.0% | 23.0% | ||
| Q2 25 | 67.2% | 11.8% | ||
| Q1 25 | 65.3% | 6.8% | ||
| Q4 24 | 217.8% | 19.3% | ||
| Q3 24 | 66.6% | 27.3% | ||
| Q2 24 | 64.6% | 24.3% |
资本支出强度EGPRGEN
| Q1 26 | 8.2% | — | ||
| Q4 25 | 40.5% | 4.1% | ||
| Q3 25 | 10.2% | 2.5% | ||
| Q2 25 | 13.7% | 3.9% | ||
| Q1 25 | 11.3% | 2.1% | ||
| Q4 24 | 36.1% | 3.2% | ||
| Q3 24 | 8.9% | 4.5% | ||
| Q2 24 | 12.6% | 3.1% |
现金转化率EGPRGEN
| Q1 26 | 1.50× | — | ||
| Q4 25 | 7.10× | 1.93× | ||
| Q3 25 | 2.07× | 3.23× | ||
| Q2 25 | 2.26× | 1.92× | ||
| Q1 25 | 2.25× | 2.57× | ||
| Q4 24 | 7.10× | — | ||
| Q3 24 | 2.23× | — | ||
| Q2 24 | 2.22× | 12.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
